NorthCrest Asset Manangement LLC Makes New Investment in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

NorthCrest Asset Manangement LLC purchased a new position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 1,196 shares of the biopharmaceutical company's stock, valued at approximately $323,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of ALNY. Larson Financial Group LLC lifted its holdings in shares of Alnylam Pharmaceuticals by 187.2% during the fourth quarter. Larson Financial Group LLC now owns 112 shares of the biopharmaceutical company's stock worth $26,000 after purchasing an additional 73 shares during the period. Park Square Financial Group LLC purchased a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter worth approximately $28,000. Whipplewood Advisors LLC increased its position in shares of Alnylam Pharmaceuticals by 208.8% during the first quarter. Whipplewood Advisors LLC now owns 105 shares of the biopharmaceutical company's stock worth $28,000 after purchasing an additional 71 shares in the last quarter. OFI Invest Asset Management purchased a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter worth approximately $35,000. Finally, Colonial Trust Co SC acquired a new position in Alnylam Pharmaceuticals during the fourth quarter worth $35,000. Institutional investors and hedge funds own 92.97% of the company's stock.

Insider Activity at Alnylam Pharmaceuticals

In related news, CEO Yvonne Greenstreet sold 19,297 shares of the firm's stock in a transaction that occurred on Monday, June 2nd. The stock was sold at an average price of $306.00, for a total value of $5,904,882.00. Following the completion of the transaction, the chief executive officer now directly owns 48,948 shares of the company's stock, valued at $14,978,088. This trade represents a 28.28% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 1.50% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on ALNY. Bank of America upped their price target on Alnylam Pharmaceuticals from $302.00 to $325.00 and gave the company a "buy" rating in a research note on Friday, March 21st. Redburn Atlantic began coverage on Alnylam Pharmaceuticals in a report on Monday, March 31st. They set a "buy" rating and a $353.00 price target on the stock. Citigroup increased their price objective on Alnylam Pharmaceuticals from $338.00 to $351.00 and gave the company a "buy" rating in a report on Friday, March 21st. Scotiabank increased their price objective on Alnylam Pharmaceuticals from $338.00 to $342.00 and gave the company a "sector outperform" rating in a report on Monday, March 31st. Finally, Morgan Stanley decreased their target price on Alnylam Pharmaceuticals from $284.00 to $268.00 and set an "equal weight" rating for the company in a research report on Friday, April 11th. One analyst has rated the stock with a sell rating, five have issued a hold rating and twenty-one have given a buy rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $319.58.

Alnylam Pharmaceuticals Stock Performance

NASDAQ ALNY opened at $307.99 on Monday. Alnylam Pharmaceuticals, Inc. has a 1-year low of $152.30 and a 1-year high of $310.22. The company has a market capitalization of $40.16 billion, a P/E ratio of -141.93 and a beta of 0.22. The business has a 50 day moving average price of $270.09 and a 200 day moving average price of $259.10. The company has a debt-to-equity ratio of 15.27, a current ratio of 2.78 and a quick ratio of 2.71.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The biopharmaceutical company reported ($0.44) earnings per share for the quarter, missing the consensus estimate of ($0.37) by ($0.07). The company had revenue of $594.19 million during the quarter, compared to analysts' expectations of $584.32 million. During the same period in the prior year, the firm earned ($0.16) earnings per share. Alnylam Pharmaceuticals's quarterly revenue was up 20.2% compared to the same quarter last year. Sell-side analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.

Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.